Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer.
AffiliationThe Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX
MetadataShow full item record
AbstractAntibodies against immune checkpoints including CTLA-4, PD-1 and PD-L1 are increasingly being used in lung cancer. They are associated with novel, immune related toxicities not previously encountered with established treatments for lung cancer including colitis, hepatitis, rashes, neuropathies and other rarer immune mediated toxicities. Although generally these are low grade, there is a potential to be life threatening if not managed promptly. Early recognition of toxicity and institution of management algorithms are key to ensuring patient safety. We review the common toxicities and provide recommendations on their management.
CitationOptimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer. 2015, 88 (2):117-123 Lung Cancer
- Checkpoint blocking antibodies in cancer immunotherapy.
- Authors: Kyi C, Postow MA
- Issue date: 2014 Jan 21
- Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer.
- Authors: Chow LQ
- Issue date: 2013
- Immune checkpoint inhibitors in lung cancer: past, present and future.
- Authors: Seetharamu N, Budman DR, Sullivan KM
- Issue date: 2016 May
- Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
- Authors: Langer CJ
- Issue date: 2015 Aug
- Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
- Authors: Garon EB
- Issue date: 2015 Oct